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Abstract
Background: Since the 1990s, evidence has accumulated of an increased prevalence of epilepsy in onchocerciasis-
endemic areas in Africa as compared to onchocerciasis-free areas. Although the causal relationship between
onchocerciasis and epilepsy has yet to be proven, there is likely an association. Here we discuss the need for
disease burden estimates of onchocerciasis-associated epilepsy (OAE), provide them, detail how such estimates
should be refined, and discuss the socioeconomic impact of OAE, including a cost-estimate for anti-epileptic drugs.
Main body: Providing OAE burden estimates may aid prevention of epilepsy in onchocerciasis- endemic areas by
inciting and informing collaboration between onchocerciasis control programmes and mental health services.
Epilepsy not only massively impacts the health of those affected, but it also carries a high socioeconomic burden
for the households and communities involved. We used previously published geospatial estimates of onchocerciasis
in Africa and a separately published logistic regression model quantifying the association between onchocerciasis
and epilepsy to estimate the number of OAE cases. We then applied disability weights for epilepsy to quantify the
burden in terms of years of life lived with disability (YLD) and estimate the cost of treatment. We estimate that in
2015 roughly 117 000 people were affected by OAE across onchocerciasis-endemic areas previously under the
African Programme for Onchocerciases control (APOC) mandate where OAE has ever been reported or suspected,
and another 264 000 persons in onchocerciasis-endemic areas where OAE has never been investigated before. The
total number of YLDs due to OAE was 39 300 and 88 700 in these areas respectively, based on a weighted mean
disability weight of 0.336. The burden of OAE is approximately 13% of the total YLDs attributable to onchocerciasis
and 10% of total YLDs attributable to epilepsy. We estimated that by 2015 the total costs of treatment with anti-
epileptic drug for OAE cases would have been a minimum of 12.4 million US$.
Conclusions: These estimates suggest a considerable health, social and economic burden of OAE in Africa. The
treatment and care for people with epilepsy, especially in hyperendemic onchocerciasis areas with high epilepsy
prevalence thus requires more financial and human resources.
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Background
Onchocerciasis, or “river blindness”, is targeted for elim-
ination, using preventive chemotherapy through mass
drug administration (MDA) with ivermectin as the pri-
mary intervention strategy [1]. Onchocerciasis is trans-
mitted by the bite of infected blackflies that breed in
fast-flowing rivers. It causes stigmatising skin disease
and vision loss, the latter eventually leading to blindness,
nearly all cases occurring in sub-Saharan Africa (SSA).
Since the 1990s, high prevalence of epilepsy in oncho-
cerciasis highly-endemic areas has increasingly been re-
ported, especially in localised foci across Africa [2–8].
In general, the prevalence of epilepsy in sub-Saharan Af-
rica is higher as compared to Asia, Europe and North
America [9]; the mean prevalence in Africa is 26% higher
than the global mean [10]. Epilepsy is more common in
Africa due to several factors, including socioeconomic
deprivations, limited access to high quality and affordable
healthcare facilities, particularly in rural areas [10]. The
Global Burden of Disease (GBD) study estimated for the
year 2015 a total of 2.66 million disability-adjusted life
years (DALYs) (95% CI: 2.15–3.28) attributed to epilepsy,
and 0.99 million DALYs (95% CI: 0.45–1.72) attributable
to onchocerciasis in SSA [11]. Various studies have esti-
mated the number of people with active epilepsy in SSA
with numbers ranging from 2.5 million to 4.5 million [10–
12]. Only a fraction of these epilepsy cases may potentially
be attributed to onchocerciasis-associated epilepsy (OAE)
[13]. An early, crude assessment of the burden of OAE in
SSA estimated approximately 100 000 cases (2011 data)
[14]. Given the negative consequences of OAE, this num-
ber should be refined with more granular data and more
advanced methods since these numbers were estimated as
a proportion of a predicted number of Onchocerca volvu-
lus-infected people in the absence of MDA. OAE-affected
individuals are subject to high economic costs, stigmatisa-
tion, discrimination [15] and premature mortality [16] if
left untreated.
In this review, we discuss the current evidence of an
association between onchocerciasis and epilepsy, and
provide the first estimates of OAE burden in terms of
expected number of cases, years of life lived with disabil-
ity (YLDs), and socioeconomic consequences for
onchocerciasis-endemic areas previously under the Afri-
can Programme for Onchocerciasis Control (APOC)
mandate. Furthermore, we suggest research priorities to
assist in building consensus on the prioritisation of the
OAE research agenda and the diligence of human and fi-
nancial resources required to prevent new OAE cases.
Are onchocerciasis and epilepsy associated?
Many well-known, non-infectious causes of epilepsy may
contribute to the burden of epilepsy in onchocerciasi-
s-endemic areas, including perinatal trauma, genetic
factors, environmental/toxic factors or nutritional de-
ficiencies that occur early in life [9]. Some parasitic
infections are known to be associated with epilepsy,
including neurocysticercosis (NCC) (due to Taenia
solium), toxoplasmosis (due to Toxoplasma gondii),
and malaria, among others [9]. For example, T. solium
in particular is endemic in many African countries
where widespread free-roaming of pigs occurs and
where pork is consumed [17], and it is estimated that
around 30% of the acquired epilepsy in T. solium-en-
demic areas of developing countries is caused by
NCC [18]. It is likely that NCC plays an important
role in SSA, although there is little knowledge on
how widespread the distribution of NCC in SSA is
[17]. The role of other parasitic infections in causing
epilepsy, including O. volvulus infection, has been much
less established. Although several cross-sectional and
case-control studies show an association between on-
chocerciasis and epilepsy [3, 4, 19, 20], it is challen-
ging to interpret such studies and demonstrate
causality in this association due to co-infection with
multiple other parasites (e.g. Plasmodium falciparum,
T. gondii, T. solium [21]) and other confounding
factors.
On the population-level, there is evidence of an associ-
ation between epilepsy and onchocerciasis. A meta-analysis
by Pion et al. [4] found an association between onchocer-
ciasis and epilepsy using population-based surveys; on aver-
age there was a 0.4% increase in epilepsy for each 10%
increase in onchocerciasis prevalence. This association is
based on studies from eight communities in seven African
countries. In only two areas (in Cameroon) NCC was re-
ported to be endemic [2, 4, 22], but additional information
from one of these areas show that a maximum of
four possible or borderline T. solium-infected individ-
uals were found out of 53 people with epilepsy [5]. It
should be noted, however, that detection of NCC
could be missed as diagnosis on the basis of serologic
tests alone would be incomplete due to low sensitivity
or specificity [23, 24]. Another review performed a re-
stricted analysis on case-control studies that con-
trolled for gender, age and place of residence [3].
This review by Kaiser et al. found a weak positive as-
sociation between skin snip positivity and epilepsy
(pooled OR = 1.29; 95% CI: 0.93–1.79, P = 0.139).
Additionally, it found that quantitative measures of
infection intensity in individuals (i.e. mean microfilar-
iae (mf), number of palpated nodules) was signifi-
cantly higher in people with epilepsy (PWE) than in
people without epilepsy (PWOE). In addition,
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preliminary results of a recent prospective study per-
formed in the Mbam valley of Cameroon, looking at
the incidence of epilepsy in O. volvulus-infected chil-
dren at baseline in 1991–1993 with a follow-up in
2017, suggest that the incidence rate ratio of epilepsy
was significantly higher in children with very high ini-
tial mf intensities/skin snips [25]. These results sug-
gest a dose-response relationship wherein the risk of
developing epilepsy in onchocerciasis patients is
higher with increasing O. volvulus mf density, sup-
porting the hypothesis that a proportion of epilepsy
cases in an onchocerciasis-endemic area are to be
caused by onchocerciasis. The effect of ivermectin on
preventing new OAE cases or on reducing the seizure
frequency of prevalent epilepsy cases is to be further
investigated, although recent studies suggest that iver-
mectin has a positive effect on epilepsy incidence [26,
27]. It is also reported that ivermectin can reduce se-
verity and frequency of epileptic seizures [28], but it
is yet unclear if this is due to the anticonvulsant
properties of ivermectin or due to flaws in the meth-
odology of the respective study. More studies are cur-
rently underway to assess the impact of MDA on
OAE [29].
There is still no definitive pathophysiologic explan-
ation for the link between onchocerciasis and epilepsy.
Studies in children with nodding syndrome (a childhood
epilepsy disorder described in O. volvulus-endemic
areas) suggest that antibodies to a protein (leiomodin-1)
present in neurons may cross-react with a similar pro-
tein that is present in the parasite O. volvulus [30]. Fur-
ther research herein would be strongly recommended.
The challenges of defining an
onchocerciasis-associated epilepsy case
In spite of the population-level association between on-
chocerciasis and epilepsy, it is difficult to attribute indi-
vidual epilepsy cases to onchocerciasis. Epilepsy is a
condition characterised by recurrent (two or more)
afebrile epileptic seizures at least 24 h apart, unprovoked
by any immediate identified cause, thus not due to an
acute intracranial or extracranial condition [31]. Individ-
uals with one unprovoked seizure but with a > 60% re-
currence risk of epileptic seizures due to an enduring
epileptogenic abnormality are also considered to be epi-
leptic [31]. Whether an epileptic seizure associated with
O. volvulus infection also has a > 60% chance of recur-
rence is unknown and may depend on the mf load and
whether the person has been treated with ivermectin.
Nonetheless, the chances of epilepsy being caused by on-
chocerciasis are more likely in areas with high onchocer-
ciasis transmission rates, evidence of O. volvulus
infection, and onset of epilepsy at young age (~ 5–
18 years old) [32]. Exclusion of other causes leading to
epilepsy, such as NCC, is often not optimal in rural set-
tings due to the unavailability of neuroimaging and re-
quires the establishment of an epilepsy-triaging system
[33]. Without the ability to exclude all other causes of
epilepsy, it is impossible to confirm a case as OAE.
Proper differentiation between causes of epilepsy in re-
mote areas across SSA, keeping the limited access to ad-
vanced technological instruments in mind, is still an
area that should receive further attention. Studies inves-
tigating the prevalence of OAE should therefore always
attempt to include a thorough medical/neurological his-
tory and examination as well as diagnosis of various
parasitic infections, including NCC, malaria, and toxo-
plasmosis, among others.
Quantifying the number of OAE cases in
sub-Saharan Africa
In order to estimate the potential burden of OAE in Af-
rica, we first identified areas where OAE has been re-
ported or suspected (independent on whether the study
found a significant association between onchocerciasis
and epilepsy). We identified 19 areas in nine countries
across SSA; Uganda [5, 26, 34, 35], Tanzania [36, 37],
Cameroon [2], Nigeria [19], Central African Republic
[20], Burundi [22], Benin [38], the Democratic Republic
of Congo [39], and South Sudan [40]. Little knowledge is
available from countries previously under the Onchocer-
ciasis Control Programme (OCP)-mandate, but we ex-
pect negligible levels of probable OAE cases due to the
long duration of vector control and MDA (OCP: 1974–
2002), including in Benin [38]. We therefore focussed on
areas previously under the APOC-mandate (“APOC-ar-
eas/countries”). For each APOC-area, population density
data for 1995 was obtained using the APOC census
(for more information, please be referred to the note
of Additional file 2).
We first estimated the number of prevalent OAE cases
prior to initiation of MDA with ivermectin (gradually in-
troduced in the region since 1995, with exception of
Kaduna, Nigeria (1991)). This was done by linking a pre-
viously published functional relationship between the
pre-control community-level prevalence of infection and
epilepsy [4] (corrected for background prevalence of epi-
lepsy in settings with zero infection prevalence) to pub-
lished estimates of the pre-control epidemiologically
mapped distribution of infection prevalence in 20 APOC
countries [41]. Details of the approach and the under-
lying assumptions are described in Table 1.
In the 18 remaining APOC-areas where OAE was re-
ported or suspected, the total population size in 1995
was 9.2 million people (Table 2). All these 18 areas re-
ceived treatment with MDA, starting between 1999 and
2012. We predict that the number of OAE cases in those
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areas was approximately 113 000 (95% CI: 53000–371
000), with an overall prevalence of 1.23% of OAE. If we
would assume that OAE has a wider geographical distri-
bution among other APOC-areas than those 18 areas,
we would expect another 362 000 (95% CI: 185000–1
085 000) OAE cases in 1995 (total population size of
81.1 million among all other APOC-areas). We further
estimated that approximately 61.5% of all OAE cases
were located in onchocerciasis hyperendemic areas (nod-
ule prevalence in adult males ≥40%), 28.7% in mesoen-
demic areas (20–40% nodule prevalence), and 9.8% in
hypoendemic areas (< 20% nodule prevalence).
To estimate the number of OAE cases by 2015, we
assumed that the number of prevalent cases increased
over time due to population growth and that OAE
prevalence declined during control of onchocerciasis
only due to lower incidence for areas with MDA and
excess mortality (i.e. assuming no direct effect of iver-
mectin on curing epilepsy, hence prevalent OAE
cases). We predict that in 2015, there were approxi-
mately 117 000 (95% CI: 50 000–441 000) prevalent
OAE cases, with an overall OAE prevalence of 0.74%
(Table 2). If we assume that OAE is also present in
onchocerciasis-endemic areas previously under the
APOC mandate and where OAE has not (yet) been
investigated, we predict an additional 264 000 (95%
CI: 109 000–1 195 000) cases in 2015.
Of course, there are some limitations in the data and
mathematical functions on which this analysis is based.
Firstly, the model uses an infection prevalence map [41]
based on the Rapid Epidemiological Mapping of Oncho-
cerciasis (REMO) surveys. The REMO surveys have their
own inherent challenges, including the use of the less
sensitive palpation of nodules as compared to skin snip-
ping. Secondly, the logistic functional relationship for
prediction of OAE prevalence by onchocerciasis infec-
tion, as reported by Pion et al., includes the at that time
available literature for which various corrections needed
to be made in order to account for history of treatment
and the various diagnostic methods used [4]. These are
the best available data to estimate – for now - most ac-
curately the number of OAE cases in APOC-countries.
In addition, we applied a more realistic background
all-cause epilepsy such as reported by the GBD for SSA
(0.36%) rather than the reported background all-cause
prevalence epilepsy by Pion et al. (0.17%).
Quantifying the disease burden: Years of life lived
with disability
DALYs are a metric used to quantify the health loss at-
tributable to a disease. They are calculated as the sum of
years of life lost (YLLs) due to premature death from a
disease and YLDs due to that disease, making DALYs a
useful measure for policy purposes because they enable
comparison of the importance of diseases. YLDs are cal-
culated by multiplying the number of years lived with a
certain disease manifestation with corresponding disabil-
ity weights. The methods for the calculation of disability
weights have been described in detail elsewhere [42, 43].
The GBD study assigned disability weights to more
than 300 disorders and diseases, including epilepsy. The
disability weight for severe epilepsy is one of the highest
with a value of 0.552 (95% CI: 0.375–0.710). Other dis-
ability weights assigned to epilepsy health states vary in
their application by seizure frequency and treatment sta-
tus. The lowest disability weight is assigned to
treatment-controlled, seizure-free epileptics with a value
of 0.049 (95% CI: 0.031–0.072) (Table 3).
Table 1 Methods for calculating onchocerciasis-associated
epilepsy (OAE) cases in the African Programme for Onchocerciasis
Control (APOC) countries in 1995 (pre-control) and in 2015
Figure 1a shows the functional relationship describing the community-level
association between the prevalence of Onchocerca volvulus skin microfilariae
and all-cause epilepsy (case definition as in the International League Against
Epilepsy guidelines [31]), as published by Pion et al. [4]. The predicted preva-
lence of epilepsy in areas with zero O. volvulus microfilariae prevalence was
removed from the analysis. The prevalence of OAE in onchocerciasis-
endemic areas was calculated by subtracting the predicted prevalence of
all-cause epilepsy for APOC-areas using the functional relationship from an
averaged all-cause background epilepsy prevalence for Sub-Saharan Africa
(0.36%, 95% CI: 0.26–0.47% [11]). We linked the functional relationship to a
published map of nodule prevalence in adult males in Africa (Fig. 1b) after
converting this map to skin microfilariae prevalence in the general
population (age 5 and above) at the pixel level (1 × 1 km raster) using a
published statistical model (Fig. 1c) [69]. We assumed that the association
between all-cause epilepsy and microfilariae prevalence was entirely driven
by geographical variation in onchocerciasis prevalence, which we assume
to be uncorrelated with other important causes of epilepsy in developing
countries, like neurocysticercosis
Next, the pre-control number of OAE cases was estimated by multiplying
the average OAE prevalence in an area (averaged over pixels) with the size
of the population at risk (based on APOC census data), assuming that the
population density is homogeneous throughout the area. We stratified the
pixels by pre-control nodule prevalence in adult males (> 0%–< 20%, ≥
20%–< 40%, ≥ 40%) and the population at risk proportional to the
number of pixels in each endemicity category. To extrapolate the number
of OAE cases to 2015, we assumed that the population at risk and hence
the potential number of OAE cases (counterfactual assuming no control)
increased annually due to population growth. Population growth between
1995 and 2015 was assumed to be 2.74% based on UN population pros-
pects for SSA [70]. For years that areas remained untreated, we assumed
that prevalence of epilepsy remained proportionally stable (i.e. as esti-
mated for 1995). Next, we corrected the number of cases for the presence
of MDA, assuming that treatment has no effect on prevalent cases of OAE
but prevents incidence of new cases after a scaling-up period of 3 years
(i.e. accounting for low treatment coverage in the first few years of MDA
programmes). Ivermectin was assumed to reduce OAE incidence to zero
(after on three years of non-optimal MDA) on the basis of studies that
suggest a reduction in the incidence of epilepsy after ivermectin treatment
[26, 27, 71]. We further assumed that once incidence of OAE is zero, the
number of prevalent OAE cases declines by 3.5% annually due to mortality,
based on a reported 70% cumulative 10-year survival probability among
epilepsy cases [16] (1−
ﬃﬃﬃﬃﬃﬃ
0:710
p ¼ 0:035). All baseline tables and calculations
are shown in Additional file 2. Furthermore, multivariate sensitivity analyses
were performed around our assumption of survival probability and
number of years of suboptimal ivermectin before OAE incidence drops to
zero (Additional file 2).
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Fig. 1 (See legend on next page.)
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In order to assign disability weights and calculate
DALYs attributable to OAE, certain pieces of informa-
tion are needed:
1. The number of deaths attributable to OAE and the
age at death;
2. The frequency of occurrence and severity of
seizures (for choosing an applicable health state),
and the proportion of patients in each of these
health states;
3. The proportion of patients with controlled epilepsy,
receiving treatment with any anti-epileptic drug (AED).
Unfortunately, this information is not widely reported in
literature. A study in an area of Cameroon highly-endemic
for onchocerciasis found that 47% of epilepsy cases in the
area experienced at least one seizure in the 6 months prior
to the study date while 16% were seizure-free with consist-
ent therapy. At epilepsy onset, 37% had experienced daily
seizures [44] (Table 4). DALY calculation for OAE is cur-
rently difficult due to the lack of information on the
age-distribution of OAE deaths required for calculating
YLLs (estimated as the sum difference between age at death
and life expectancy at death). However, YLDs can be es-
timated as the product of the number of prevalent OAE
cases and the disability weight for OAE. If the asser-
tions around the epidemiological relationship as pub-
lished by Pion et al. [4] are representative for the
distribution of OAE in all countries previously under
the APOC mandate, we estimate that in 2015 there
were approximately 39 300 YLDs attributable to OAE
in the areas where OAE has been reported or suspected
and potentially 88 700 YLDs attributable to OAE in
other areas where OAE has not been reported up to
now. Calculations can be seen in Table 5.
There are some important limitations to these YLD esti-
mates. First of all, one study is likely not representative of
all epilepsy cases in Africa. We have therefore performed
an additional sensitivity analysis to assess the robustness
of our YLD estimates by comparing our estimated
weighted mean disability weight with those of the GBD
(Additional file 2: chapter 2). It is likely that the propor-
tion of OAE cases experiencing different levels of epilepsy
severity vary by mf intensity level and by treatment his-
tory. It is also possible that severity of OAE may vary by
geographical location due to different O. volvulus species
with differing pathogenic potential, such is the case for
blindness due to onchocerciasis [45]. Variation is also ex-
pected by level of healthcare access, given that a lower dis-
ability weight is applied to medically-controlled epilepsy
cases. The disability weights from the GBD as shown in
Table 3 are not collected for different age groups, and it
would be interesting to validate the different assigned se-
verity weights among especially children and young adults
with epilepsy in onchocerciasis-endemic areas, as they are
the ones with highest OAE prevalence. Ultimately, with so
little available published information on the clinical details
of the disease, it is hard to know how close this estimate is
to the truth. However, the burden of OAE can be substan-
tial as compared to other clinical manifestations of oncho-
cerciasis. If we assume that OAE occurs throughout all
onchocerciasis-endemic countries previously under the
APOC mandate, the total YLD attributable to OAE would
be 128 000 YLDs (39 300 + 88 700 = 128 000 YLDs) in
2015. The GBD estimated 989 653 YLDs due to onchocer-
ciasis (i.e. skin disease, visual impairment, blindness) in
the year 2015 for SSA [11]. The actual onchocerciasis bur-
den (in terms of YLDs) would be approximately 12%
higher if we would also take account of OAE. Out of the
3.5 million prevalent epilepsy cases in SSA (GBD estimate
(See figure on previous page.)
Fig. 1 Used published relationships and onchocerciasis map to calculate the pre-control prevalence of onchocerciasis-associated epilepsy. a
Community-level all-cause epilepsy prevalence versus corrected onchocerciasis microfilariae prevalence, as published by Pion et al. [4]. b Map of
the estimated pre-control prevalence of palpable nodules in the 20 African Programme for Onchocerciasis Control countries, as published by
Zouré et al. [41]. c Predicted skin mf prevalence in the general population, given observed nodule prevalence in adult males, as published by
Coffeng et al. [69]. Permission for publication of all figures was granted from the journals and authors
Table 2 Estimated number of onchocerciasis-associated epilepsy cases with 95% confidence intervals in the African Programme for
Onchocerciasis Control-areas for two time periods
1995 2015
Areas where presence of OAE is reported / suspected Number of cases 93 (95% CI: 40–352) 117 (95% CI: 50–441)
Total population 9 214 15 821
Areas where presence of OAE has not yet been investigated Number of cases 205 (95% CI: 85–922) 264 (95% CI: 109–1195)
Total population 81 116 139 282
Total Number of cases 298 (95% CI: 124–1274) 381 (95% CI: 158–1636)
Total population 90 330 155 103
Numbers are presented in thousands
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for 2015 [11]), 11% would be associated with onchocercia-
sis. Using the weighted mean disability weight for epilepsy,
the YLDs due to OAE in APOC-areas forms about 10% of
the estimated YLDs in SSA due to epilepsy overall (GBD
estimate 2015: 1.31 million YLDs [11]).
Estimating the socioeconomic burden of OAE
Similar to the distribution of onchocerciasis, OAE occurs
almost exclusively in remote areas where people are
already disenfranchised by their socioeconomic status. Sub-
sistence farming is generally the primary source of income,
and adequate healthcare is often inaccessible [46]. OAE
compounds this burden through the accrual of additional
direct, indirect and intangible health-related costs [47].
Direct health-related costs include all payable fees re-
lated to care-seeking and medical treatment including:
payment for transportation to and from a medical facil-
ity; costs of diagnostic testing, medication and physician
consultation; cost of follow-up consultation and/or hos-
pitalisation; and costs related to home-based care such
as the cost accrued from an increased need for personal
hygiene products like soap. Beyond the cost of diagnos-
ing and treating OAE, PWE are more likely to acquire
other direct health-related costs related to their higher
propensity for cooking accidents that may cause severe
burns requiring treatment and other incidental injuries.
These expenditures reduce the amount of basic financial
resources available to the household [48, 49]. Unlike on-
chocerciasis which has one drug of choice for its control,
epilepsy treatments are multiple and their indications
are different [50]. Data on the cost of epilepsy manage-
ment in Africa is currently scarce. Findings from
Burundi, Zambia, and South Africa suggest an annual
cost of medication alone ranging from US$ 10 to US$
48 [51–53]. Table 6 shows the average costs of one unit
medicine for a PWE (other costs related to the medical
management of PWE are currently not available).
To estimate the cost of treatment for all OAE cases in
APOC countries, we multiplied the predicted number of
cases in 2015 by the weighted mean of annual treatment
costs of AEDs. No added cost is attributed to account for
ivermectin as it is freely distributed by the Mectizan® Do-
nation Programme [54]. We estimate that the total cost
for treating all OAE cases in onchocerciasis-endemic areas
where OAE has previously been reported or suspected
would have been approximately US$12.4 million (117 000
OAE cases × US$ 106.31) in 2015. If OAE would occur in
the whole of APOC-areas, we estimate there would be an
additional US$28.1 million required (264 000 OAE cases ×
US$106.31) to treat all additional cases. These figures
make up only part of the total direct cost since they do
not account for cost of transportation and consultation/
hospitalisation. The dosages are currently set to levels that
are used in clinical practice of African settings [55]. How-
ever, non-adherence of patients to AED may be quite high
in some settings (59–63%), overestimating the costs of
AEDs as compared to actual usage [9, 56].
Furthermore, these estimates do not reflect the indirect
and intangible costs of OAE. Indirect costs are related to
lost productivity that is often a consequence of delayed
diagnosis and treatment of epilepsy cases due to the lim-
ited availability and access to specialists trained in epilepsy
care in Africa [57]. Several African countries reported a
treatment gap of between 68 and 82% [58–60]. Untreated
epilepsy is often associated with lower employment and
education levels, and lower socioeconomic status [61].
Table 3 Different sequela of epilepsy that could be applied to onchocerciasis-associated epilepsy (adapted from [72])
Sequelae Health State Lay Description Disability Weight
Severe epilepsy Severe (seizures ≥
once per month)
An individual has sudden seizures one or more times each month, with violent
muscle contractions and stiffness, loss of consciousness, and loss of urine or bowel
control. Between seizures the person has memory loss and difficulty concentrating.
0.552 (0.375–0.71)
Less severe epilepsy Less severe (seizures <
once per month)
An individual has sudden seizures two to five times a year, with violent muscle
contractions and stiffness, loss of consciousness, and loss of urine or bowel
control.
0.263 (0.173–0.367)
Seizure-free,
treated epilepsy
Treated without fits An individual has a chronic disease that requires medication every day and
causes some worry but minimal interference with daily activities.
0.049 (0.031–0.072)
Table 4 Frequency of different health states (indicating different severity levels) of epilepsy in an onchocerciasis hyperendemic area,
associated disability weights for each health state (GBD), and calculation of the weighted mean disability weight across health states
(weighted for the proportion of cases in each health state, based on Prischich et al. 2008 [44])
Health state Proportion of epilepsy patients with health state Disability weight
Severe epilepsy 37% 0.552
Less severe epilepsy 47% 0.263
Seizure-free, treated epilepsy 16% 0.049
Weighted mean disability weight, weighted by the proportion of cases in each health state 0.336
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Children with epilepsy may be banned from school, and
adults with epilepsy may be barred from marriage or em-
ployment even if seizures do not render their work unsafe
[62, 63]. Intangible costs are derived from the emotional
and social impact of illness. OAE affects both PWE and
caregivers. Caregivers may experience inordinate levels of
stress, sleepless nights or burnout related to their respon-
sibility of caring for the patient or their worry about the
affected child wandering away [49]. Limited access to
AEDs for PWE results in uncontrolled seizures with a
high frequency of intellectual disability and psychiatric
problems, rendering them extremely vulnerable to abuse
and neglect. There have been anecdotal reports that sug-
gest that women with epilepsy in SSA are sexually
exploited, abused and have to exchange sex for basic ne-
cessities more frequently than unaffected women. This
sexual assault also increases their risk for HIV/AIDS and
other sexually transmitted infections [62] and if they be-
come pregnant, they may be left with the additional bur-
den of caring for a child [49].
A major challenge in holistically estimating the socioeco-
nomic burden due to OAE is the difficulty in measuring
costs because there are many unknown factors (e.g. loss of
economy due to time away from work, denial from work of
PWE). Therefore, these estimates do not reflect the indirect
and intangible costs of OAE. Although we recognise the
limitations of providing only costs of medicines, it appears
that investing in direct costs (principally treatment with
AED) would likely produce benefits in indirect costs
(increased productivity) and intangible costs (improved
quality of life), all outweighing the initial investment [10,
51]. Such cost estimations assist in making sure necessary
resources become available and that the infrastructure can
be set in place to target interventions in high-risk
onchocerciasis-endemic communities.
Towards more accurate burden estimates
We have described the major challenges and limitations
in our quantification of the number of cases, disease
burden estimates (YLDs), and socioeconomic burden.
These challenges and limitations can be solved through
the acquisition of new and different types of data as well
the use of more sophisticated statistical procedures or
mathematical models. More data is needed on the preva-
lence of O. volvulus and epilepsy at the community-level
of various levels of onchocerciasis endemicity. While
Table 5 Methods for calculating YLDs attributable to
onchocerciasis-associated epilepsy (OAE)
The disability weight associated with epilepsy depends on the disease
severity (see Table 3). We calculated a weighted mean disability weight
for epilepsy across the different severity levels, weighting the health
state-specific disability weights by the proportion of cases in that health
state (Table 4). The proportion of cases in each health state is derived
from clinical data of epilepsy severity and frequency in an onchocerciasis
hyperendemic area [44]. We assume that the weighted mean disability
weights are also applicable to OAE. We multiplied the weighted mean
disability weights with the number of prevalent OAE cases to calculate
total YLDs attributable to OAE, independently for the various areas. Two
types of sensitivity analyses were performed to demonstrate the range
in estimates yielded by varying one disability weight value at a time
(Additional file 2: Figure S1 and S2).
Total YLDs attributable to OAE for 2015 in areas with suspected/
reported OAE:
0.336 × 117 000 = 39 300 (95% CI: 16800–148 200)
This total estimation of YLDs is based on areas where OAE has been
reported or suspected (same 18 areas as stated before).
Total YLDs attributable to OAE for 2015 in areas where the presence of
OAE has not yet been investigated: 0.336 × 264 000 = 88 700 (95% CI: 36
600–401 500)
This total estimation of YLDs is based on onchocerciasis-endemic areas
previously under the APOC mandate where OAE has not been reported
or suspected.
Table 6 Costs related to medication for treating one person with epilepsy in US$. Adapted from [55]
Name medication Usage Median buyer price/
day per treated
person (US$)a
Defined daily
dose (DDD)b
Median buyer
price/year per
treated person (US$)
Used by percentage
of all epilepsy
patients [56]
Phenobarbital ~
100 mg (1×)
Used for all forms of epilepsy. Most used AED in
Sub-Saharan Africa which serves as first-line,
because it is relatively cheap and available [10].
$0.0141 100 mg $5.15 74.6%
Carbamazepine ~
200 mg (4–5×)
Used for focal seizures [50]. $0.14 1000 mg $255.50 27.4%
Phenytoin ~
100 mg (3×)
Used in some generalised seizures and
status epilepticus [50].
$0.0449 300 mg $49.17 22.2%
Valproate ~
500 mg (3×)
Used for all forms of epilepsy including
absences, atonic and myoclonic seizures [50].
$0.1339 1500 mg $146.62 14.7%
Weighted-average cost of AEDc US$ 106.31
Note: aThese figures on dosages per drug are based on the daily average dosage that are generally applied in rural African settings, and obtained by comparing
several buyer prices for the same product in 2015 [55]
bThe defined daily dose (DDD) methodology was designed by the WHO to help in following and comparing cost trends at the international level, but not to be
used for detailed reimbursement, therapeutic group reference pricing or other specific pricing decisions [55]
cThe weighted average was calculated by ((100 mg × 1 × cost Phenobarbital unit price × 365 days × 0.746) + (200 mg × 5 × cost Carbamazepine unit price ×
365 days × 0.274) + (100 mg × 3 × cost Phenytoin unit price × 365 days × 0.222) + (500 mg × 3 × cost Valproate unit price × 365 days × 0.147))/1.0 total
population = US$ 106.31
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some data has already been collected and published [4],
there are a number of challenges in utilising it for estima-
tion. Due to the different diagnostic methods and case
definitions that are employed in different studies, the mea-
sured prevalence cannot be assumed to be comparable
due to the divergent sensitivities and specificities. For epi-
lepsy, an adapted case definition applicable in remote
areas, including onchocerciasis-endemic areas, to establish
aetiology of epilepsy in absence of neuroimaging would
help in making study results comparable in future re-
search and comparisons should be made with older diag-
nostics and case definitions to help equate and interpret
results from past research.
Secondly, age- and sex-stratified information is vital in
order to capture age- and sex-specific trends in preva-
lence and disease burden estimates. Epilepsy in
onchocerciasis-endemic areas may have a different age
pattern in the onset of epilepsy as compared to oncho-
cerciasis non-endemic areas, with a peak onset of epi-
lepsy between ages 10 and 15 years [7, 8, 64]. Age- and
sex-stratified data are essential to be able to reproduce
disease trends in the prevalence of OAE that can subse-
quently inform treatment policy, research and drug de-
velopment efforts targeted at these higher-risk groups.
In addition, data on the sex- and age-distribution of
OAE deaths is required in order to calculate DALYs.
Note that the collection of such data, however, may be
quite challenging without the ability to confirm that the
epilepsy is caused by onchocerciasis.
Thirdly, there is limited data available about the prema-
ture mortality due to epilepsy. In a study in an
onchocerciasis-endemic region in Cameroon the relative
risk of death among PWE was 6.2 times (95% CI: 2.7–
14.1) than among those without epilepsy [16]. Additional
assessments of excess mortality due to OAE are necessary
to refine our assumption of an excess mortality of 3.5%
that we applied in the statistical model presented here,
based on the study by Kamgno et al. [16]. This would have
the effect of a different survival rate of OAE cases (age-s-
tratified), and henceforth a better estimate of the inci-
dence and prevalence of OAE cases across Africa.
Fourthly, very little data is available concerning the
current incidence and prevalence of OAE in the majority
of sub-Saharan African countries where onchocerciasis
is endemic. The available data is concentrated in limited
and very focal study sites. This both limits our ability to
develop accurate disease burden estimates for vast areas
as well as limits our understanding of the epidemiology
of the OAE. We have now provided stratified estimates
of OAE cases for areas where OAE has been reported or
suspected and areas where we do not have any informa-
tion from. Greater geographical coverage of OAE sur-
veys is essential for making estimates more precise and
ensuring that the full burden of OAE is captured.
Lastly, in addition to more refined and robust data, es-
timates of disease quantification can be refined through
the use of modelling frameworks, both statistical and
mathematical. Statistical models for the association be-
tween infection and morbidity may not well capture
non-linearities in population dynamics, but they can
make sophisticated estimates of current and future bur-
den. In the past, a Bayesian, hierarchical meta-regression
model was used to successfully estimate the burden at-
tributable to epilepsy globally from 1980 to present [32].
Mathematical models may better capture transmission
dynamics of onchocerciasis [65–67], such that OAE de-
velopment is dependent on mf-production with a dam-
age trigger after which epilepsy is allowed to develop. It
is possible that damage susceptibility is age-dependent,
which could be taken into account in a mathematical
model. Likewise, the degree of excess mortality can be
accounted for.
Policy implications
Since epileptic seizures can, under certain circum-
stances, be well controlled and an individual’s quality of
life can be restored with treatment, there are significant
gains that can be made for epilepsy patients. The major-
ity of epilepsy patients in Africa do not receive appropri-
ate care, due to limited financial means of households,
high costs of AED, lack of proper diagnostics, and/or in-
sufficient number of trained health workers or drug sup-
plies [68]. Scaling-up of care (e.g. additional support and
treatment with AED through decentralised services) is
urgently needed [10]. The link between onchocerciasis
and epilepsy may be exploited in two ways.
Firstly, the possible effect of onchocerciasis control ef-
forts on the incidence of epilepsy may be reason to put
in extra resources for the intensification of onchocercia-
sis elimination activities in highly endemic onchocercia-
sis areas where high prevalence rates of epilepsy are
found [32]. Secondly, health systems can be strength-
ened in (often remote) highly endemic onchocerciasis
areas with high epilepsy prevalence, to enhance timely
referral of epilepsy patients (irrespective of the cause of
the epilepsy). Community-directed distributors of iver-
mectin could be trained to identify potential epilepsy
cases and refer them to the general health system, to en-
sure that they receive proper anti-epilepsy treatment.
Such efforts may perhaps have little impact on the total
epilepsy prevalence in SSA, but it would even so have
adjuvant advantages for both onchocerciasis and epilepsy
control and may even prevent the potentially significant
impact of OAE. In some areas, this may require im-
provements in accessibility and affordability of health-
care services in order to increase utilisation. Most PWE
will respond to AED in stock, at least with a reduction
in seizure frequency, and therefore, if they are picked up
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in the community and referred, will benefit from the
health services available.
Research priorities
We have demonstrated that there is a need to improve
estimates of the burden of OAE by country, age and sex,
including the calculation of YLLs, YLDs and DALYs at-
tributable to OAE. We have identified six research prior-
ities that need to be addressed in order to improve our
understanding of OAE and make our estimates more
precise (Table 7). These priorities should be included in
the research and policy agendas of both onchocerciasis
and epilepsy programmes in Africa. Sustained and inten-
sified funding is required to prompt onchocerciasis
elimination efforts in general, with special focus on
high transmission zones (often associated with high
potential of increased epilepsy prevalence). In
addition, these research priorities may motivate health
policy-makers to increase funding to health systems
across SSA in general, with the aim of tackling epi-
lepsy in these areas.
Conclusions
Based on our estimates the number of persons with OAE
in 2015 is estimated to be 117 000 (95% CI: 50 000–441
000) in onchocerciasis-endemic areas where OAE has
been reported or suspected and 264 000 (95% CI:
109 000–1 195 000) in onchocerciasis-endemic areas
where OAE has not yet been investigated. An educated
analysis of the burden of OAE is imperative in order to
delineate the type and scope of public health responses it
requires, both in terms of efficient control interventions
and availability of resources. Although the estimates pre-
sented here need further refinement, they provide a first
step towards quantifying the burden of OAE that we can
expect today. These numbers are useful for policy-makers
and onchocerciasis and epilepsy programme managers
who need to be aware of the public health impact caused
by epilepsy in onchocerciasis-endemic areas. Intensifica-
tion of onchocerciasis control efforts and/or increases in
resources for epilepsy healthcare services would then be
imperative for most affected areas. People living in
onchocerciasis-endemic regions need to understand the
full implication and potential gains of supporting and
adhering to MDA programmes.
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